The Study of Safely and Efficacy by Telmisartan Therapy in Patientswith Essential Hypertension

Objective:Toinvestigate the safety and efficacy by telmisartan thetapy in patients with mild or middle type essential hyper- tension. Methods: 121 patients with mild or middle type essential hypertension were divided into two groups randomly: Group one was given with 80mg telmisartan per day in the morning , group two was given with 50mg loaartan. Larsting 6 weeks treatment without remarkable effect,hydrochlorothiazide was added . The renal function, hepatic function, plasma electrolye , plasminogen activator inhibiter-1 (PAI-l), fibrinogen(FG), C-creatin protein(CRP), plasma uric-acid and ambulatory blood pressure were compared before and after treatment in the groups. The cardiovascular events or incidence of stroke and drug adverse reaction were following up for 6 months at least. Results: Results: In the group one the total effective rate of blood control was 78.7% (48/61 case). The degree of blood lowing was25.6/14.6mmHg. The trough-to peak(T/P) ratio was: Systolic blood pressure(SBP) 0.88,Diastolic blood pressure(DBP)0.89. Hydrochorothiazade (HCT) was taken in 9 cases who appeared inefficacy after 6 weeks telmisartan therapy and the remarkable efficacy was 25% after adding HCT.In the group two the total effective rate of blood control was 75.0% (45/60} and the blood lowing was 22.1/ 12. 1mmHg.The T/P ratio was: SBP 0.86,DBP 0.87.Hydrochorothizide was added when it appeared inefficacy in 8 cases after 6 weeks losartan therapy and the remarkable efficacy was 21.1%. Comparing to group two, group one had significantly difference in degree of blood lowing (P0.05) and had significantly difference on mean SBP and mean DBP by ambulatory monitoring(P0.05). The PAI-1, FG , CRP were remarkably lowing after treatment in either telmisartan or losartan group (P0.05) but telmisartan was more remarkable(P0.05). After 6 months following up the cardiovascular events and stroke were similar in two groups. The drag adverse reaction was mild and similar in two groups. Conclusion: There are safety, efficacy, stability,less adverse reaction, convenience for taking in treatment with patients who suffer from mild or middle essential hypertension. It is recommended that telmisartan as one kind of an- giotensin receptor antagonists would be chosen for first-line of anti-hypertensive therapy.